Politics · India Bureau
Sun Pharma secures global rights to $3.7bn cholesterol drug
Sun Pharmaceutical Industries has acquired commercialisation and manufacturing rights to LIB Therapeutics' once-monthly cholesterol treatment across markets outside the United States and China, following European Union approval.
LSN India ·
The deal grants Sun Pharma exclusive rights to market and produce the innovative cholesterol medication, tapping into a global market valued at $3.7 billion. The drug's once-monthly dosing mechanism represents a significant advancement in treatment convenience compared to existing daily regimens, potentially improving patient compliance in managing cardiovascular risk factors.
The European Union's approval of the therapy strengthens Sun Pharma's position in the global specialty pharmaceutical market and expands its cardiovascular portfolio. The company will handle manufacturing and commercialisation responsibilities across key markets in South Asia, Southeast Asia, and other regions outside the US and China.
Sun Pharmaceutical, one of India's largest pharmaceutical companies, has increasingly focused on acquiring rights to innovative drugs to complement its generic and specialty medicine offerings. This strategic move aligns with the company's expansion into high-value therapeutic segments where patented drugs command premium pricing.
The cholesterol drug market remains highly competitive, with multiple treatment options available globally. However, the once-monthly administration profile offers a differentiation point that could capture market share from traditional daily therapies among patients seeking improved convenience and potentially better adherence rates.